Ashish Chabria

Ashish Chabria is a healthcare investment banker with more than 30 years of experience providing corporate-finance and M&A solutions to life sciences companies across biotechnology, specialty pharmaceuticals, biomanufacturing, diagnostics, lab tools, and medical devices. In October 2021 he founded Chabria Advisory LLC, a Delaware-registered, New York-area boutique offering M&A, strategic, and corporate-finance advisory to healthcare and life sciences clients, drawing on deep transaction expertise and a global network.

Before launching his own firm, Chabria served as Managing Director and Head of Health Care at TAP Advisors, a New York–based M&A, strategic, and corporate-finance advisory boutique founded in late 2009. Earlier in his career he held Head Managing Director, Health Care Banking responsibilities associated with Mizuho (Mizuho Financial Group / Mizuho Securities USA), and served as an Executive Director at UBS Investment Bank, where he was a coverage officer for healthcare-industry relationships. He also worked as Vice President, Strategy & Corporate Development at Pharmascience, a pharmaceutical manufacturer, and began his banking career as an Associate in Mergers & Acquisitions at JPMorgan Chase.

Chabria holds a B.A. in Accounting & Information Systems from Queens College (CUNY). His work has centered on helping innovators bring transformative science to patients — a mission he has described as becoming deeply personal after his own late-stage head and neck cancer diagnosis and recovery, which has left him particularly interested in supporting other head and neck cancer patients.

• Career specialization in life sciences finance — biotech, specialty pharma, biomanufacturing, diagnostics, lab tools, and medtech — spanning M&A, private financings, and cross-border/international transactions.
• Source data classifies him as an angel/seed-stage investor in healthcare; however, no specific check size, fund, or portfolio has been publicly disclosed, so these parameters remain unverified.
• His advisory (and likely investing) lens favors companies with transformative or differentiated science intended to reach patients — consistent with his stated personal mission.
• Strong orientation toward founders and companies needing focused corporate-finance strategy and transaction execution, reflecting a banker's rather than a pure-fund investor's approach.

No individually named angel or seed investments by Ashish Chabria could be verified from public sources. His documented track record is as an M&A and corporate-finance advisor to life sciences companies (via TAP Advisors, Mizuho, UBS, JPMorgan, and now Chabria Advisory) rather than as a disclosed portfolio investor. Specific advised transactions were not publicly attributed to him by name in available sources.